#GLP-1 class

Coverage of the GLP-1 receptor agonist family and its successors.

A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.

A 2026 review found neutral or potentially better outcomes with perioperative GLP-1 use, but all three comparative studies were retrospective.

A 573-person trial found lower HbA1c and weight with semaglutide plus reduced insulin than with further insulin glargine titration.

A non-randomized Japanese cohort reported similar six-month weight loss with 2.5 mg and 5 mg tirzepatide, without proving dose equivalence.

A 2026 meta-analysis links tirzepatide to lower cardiorenal biomarkers, while functional and kidney findings remain based on single trials.

A mouse study tested sulforaphene-loaded α-lactalbumin nanomicelles against semaglutide, but it provides no human efficacy or safety evidence.

Australian sales and PBS data show rapid GLP-1 medicine growth, with nearly half of estimated use accessed privately in the final study year.

A retrospective cohort linked higher-dose oral semaglutide and SGLT-2 inhibitor use with improved arterial stiffness, without proving causation.

A 2026 review found a rare NAION safety signal around GLP-1 medicines, led mainly by observational semaglutide data.

A 2026 narrative review maps dual glucagon and GLP-1 agonists for obesity and MASH, while head-to-head evidence remains unresolved.

A 2026 dermatology review frames so-called Ozempic face as weight-loss-associated facial change, not a proven drug-specific diagnosis.

A target trial emulation linked preconception incretin therapy with fewer adverse pregnancy outcomes than metformin, but it cannot prove causation.